Robert I Liem1,2, Sophie Lanzkron3, Thomas D Coates4, Laura DeCastro5, Ankit A Desai6, Kenneth I Ataga7, Robyn T Cohen8, Johnson Haynes9, Ifeyinwa Osunkwo10, Jeffrey D Lebensburger11, James P Lash12, Theodore Wun13, Madeleine Verhovsek14, Elodie Ontala15, Rae Blaylark16, Fares Alahdab17, Abdulrahman Katabi17, Reem A Mustafa18. 1. Division of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 2. Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL. 3. Division of Adult Hematology, School of Medicine, Johns Hopkins University, Baltimore, MD. 4. Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, CA. 5. Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA. 6. Krannert Institute of Cardiology, School of Medicine, Indiana University, Indianapolis, IN. 7. Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN. 8. Division of Pediatric Pulmonary and Allergy, Boston Medical Center, School of Medicine, Boston University, Boston, MA. 9. Division of Pulmonary Disease, College of Medicine, University of South Alabama, Mobile, AL. 10. Division of Hematology, The Levine Cancer Institute, Atrium Health, Charlotte, NC. 11. Division of Pediatric Hematology/Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL. 12. Division of Nephrology, Department of Medicine, University of Illinois at Chicago, Chicago, IL. 13. Division of Hematology and Oncology, School of Medicine, University of California Davis, Sacramento, CA. 14. Division of Hematology and Thromboembolism, McMaster University, Hamilton, ON, Canada. 15. Milwaukee, WI. 16. Minneapolis, MN. 17. Division of General Internal Medicine, Mayo Medical School, Rochester, MN; and. 18. Division of Nephrology and Hypertension, School of Medicine, University of Kansas, Kansas City, KS.
Abstract
BACKGROUND: Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. METHODS: ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. CONCLUSIONS: Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.
BACKGROUND: Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. METHODS: ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. CONCLUSIONS: Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.
Authors: Nargues A Weir; Rehan Saiyed; Shoaib Alam; Anna Conrey; Himanshu D Desai; M Patricia George; Jennifer H Keeley; Elizabeth S Klings; Alem Mehari; James G Taylor; Caterina P Minniti; Gregory J Kato Journal: Haematologica Date: 2017-01-25 Impact factor: 9.941
Authors: Pablo Alonso-Coello; Holger J Schünemann; Jenny Moberg; Romina Brignardello-Petersen; Elie A Akl; Marina Davoli; Shaun Treweek; Reem A Mustafa; Gabriel Rada; Sarah Rosenbaum; Angela Morelli; Gordon H Guyatt; Andrew D Oxman Journal: BMJ Date: 2016-06-28
Authors: Charles T Quinn; Santosh L Saraf; Victor R Gordeuk; Courtney D Fitzhugh; Susan E Creary; Prasad Bodas; Alex George; Ashok B Raj; Alecia C Nero; Catherine E Terrell; Lisa McCord; Adam Lane; Hans C Ackerman; Yu Yang; Omar Niss; Michael D Taylor; Prasad Devarajan; Punam Malik Journal: Am J Hematol Date: 2017-07-19 Impact factor: 10.047
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Victor R Gordeuk; Vandana Sachdev; James G Taylor; Mark T Gladwin; Gregory Kato; Oswaldo L Castro Journal: Am J Hematol Date: 2008-01 Impact factor: 10.047
Authors: Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245
Authors: Ariel Izcovich; Adam Cuker; Robert Kunkle; Ignacio Neumann; Julie Panepinto; Menaka Pai; Matthew Seftel; Matthew C Cheung; Richard Lottenberg; Michael Byrne; Robert Plovnick; Deirdra Terrell; Jennifer L Holter-Chakrabarty; Benjamin Djulbegovic; Lisa K Hicks; Wojtek Wiercioch; Robby Nieuwlaat; Holger J Schünemann Journal: Blood Adv Date: 2020-05-12
Authors: Wojtek Wiercioch; Robby Nieuwlaat; Elie A Akl; Robert Kunkle; Kendall E Alexander; Adam Cuker; Anita Rajasekhar; Pablo Alonso-Coello; David R Anderson; Shannon M Bates; Mary Cushman; Philipp Dahm; Gordon Guyatt; Alfonso Iorio; Wendy Lim; Gary H Lyman; Saskia Middeldorp; Paul Monagle; Reem A Mustafa; Ignacio Neumann; Thomas L Ortel; Bram Rochwerg; Nancy Santesso; Sara K Vesely; Daniel M Witt; Holger J Schünemann Journal: Blood Adv Date: 2020-05-26
Authors: Solomon Johnson; Victor R Gordeuk; Roberto Machado; J Simon R Gibbs; Mariana Hildesheim; Jane A Little; Gregory J Kato; Mark T Gladwin; Mehdi Nouraie Journal: Am J Hematol Date: 2021-10-20 Impact factor: 10.047
Authors: Payal Shah; Silvie Suriany; Roberta Kato; Adam M Bush; Patjanaporn Chalacheva; Saranya Veluswamy; Christopher C Denton; Kelly Russell; Maha Khaleel; Henry J Forman; Michael C K Khoo; Richard Sposto; Thomas D Coates; John C Wood; Jon Detterich Journal: Am J Hematol Date: 2020-10-12 Impact factor: 10.047
Authors: Julie Kanter; Shannon Phillips; Alyssa M Schlenz; Martina Mueller; Mary Dooley; Logan Sirline; Robert Nickel; Robert Clark Brown; Lee Hilliard; Cathy L Melvin; Robert J Adams Journal: J Pediatr Hematol Oncol Date: 2021-11-01 Impact factor: 1.289
Authors: Anis Rabbani Nourani; A K M Fazlur Rahman; Brandi Pernell; Mary H Maddox; Lee Hilliard; Jeffrey Lebensburger; Ammar Saadoon Alishlash Journal: J Clin Sleep Med Date: 2021-02-01 Impact factor: 4.062